IPA vs. KALA, CNTB, CELU, XLO, DYAI, ALVR, ATRA, OSTX, OVID, and NBRV
Should you be buying ImmunoPrecise Antibodies stock or one of its competitors? The main competitors of ImmunoPrecise Antibodies include KALA BIO (KALA), Connect Biopharma (CNTB), Celularity (CELU), Xilio Therapeutics (XLO), Dyadic International (DYAI), AlloVir (ALVR), Atara Biotherapeutics (ATRA), OS Therapies (OSTX), Ovid Therapeutics (OVID), and Nabriva Therapeutics (NBRV). These companies are all part of the "pharmaceutical products" industry.
ImmunoPrecise Antibodies vs.
ImmunoPrecise Antibodies (NASDAQ:IPA) and KALA BIO (NASDAQ:KALA) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, media sentiment, risk, profitability, dividends, community ranking and earnings.
ImmunoPrecise Antibodies currently has a consensus price target of $5.00, indicating a potential upside of 1,195.00%. KALA BIO has a consensus price target of $15.00, indicating a potential upside of 125.90%. Given ImmunoPrecise Antibodies' higher probable upside, equities research analysts clearly believe ImmunoPrecise Antibodies is more favorable than KALA BIO.
ImmunoPrecise Antibodies has a beta of 0.04, indicating that its stock price is 96% less volatile than the S&P 500. Comparatively, KALA BIO has a beta of -2.03, indicating that its stock price is 303% less volatile than the S&P 500.
ImmunoPrecise Antibodies has higher revenue and earnings than KALA BIO. KALA BIO is trading at a lower price-to-earnings ratio than ImmunoPrecise Antibodies, indicating that it is currently the more affordable of the two stocks.
In the previous week, ImmunoPrecise Antibodies had 2 more articles in the media than KALA BIO. MarketBeat recorded 2 mentions for ImmunoPrecise Antibodies and 0 mentions for KALA BIO. ImmunoPrecise Antibodies' average media sentiment score of 0.83 beat KALA BIO's score of 0.00 indicating that ImmunoPrecise Antibodies is being referred to more favorably in the media.
KALA BIO received 290 more outperform votes than ImmunoPrecise Antibodies when rated by MarketBeat users. However, 91.67% of users gave ImmunoPrecise Antibodies an outperform vote while only 66.89% of users gave KALA BIO an outperform vote.
KALA BIO has a net margin of 0.00% compared to ImmunoPrecise Antibodies' net margin of -114.50%. ImmunoPrecise Antibodies' return on equity of -73.74% beat KALA BIO's return on equity.
6.7% of ImmunoPrecise Antibodies shares are owned by institutional investors. Comparatively, 24.6% of KALA BIO shares are owned by institutional investors. 6.8% of ImmunoPrecise Antibodies shares are owned by insiders. Comparatively, 8.3% of KALA BIO shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Summary
ImmunoPrecise Antibodies beats KALA BIO on 11 of the 16 factors compared between the two stocks.
Get ImmunoPrecise Antibodies News Delivered to You Automatically
Sign up to receive the latest news and ratings for IPA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ImmunoPrecise Antibodies Competitors List
Related Companies and Tools
This page (NASDAQ:IPA) was last updated on 2/22/2025 by MarketBeat.com Staff
Free IPA Stock Alerts